MABGEL 1: First Phase 1 Trial of the Anti-HIV-1 Monoclonal Antibodies 2F5, 4E10 and 2G12 as a Vaginal Microbicide

• Georgina C. Morris,

  Affiliation Centre for Immunology and Infection, Hull York Medical School, University of York, York, United Kingdom

  ⨯
• Rebecca C. Wiggins,

  Affiliation Centre for Immunology and Infection, Hull York Medical School, University of York, York, United Kingdom

  ⨯
• Sarah C. Woodhall,

  Affiliation Centre for Immunology and Infection, Hull York Medical School, University of York, York, United Kingdom

  ⨯
• J. Martin Bland,

  Affiliation Department of Health Sciences, University of York, York, United Kingdom

  ⨯
• Carol R. Taylor,

  Affiliation Hull York Medical School Experimental Medicine Unit, York Teaching Hospitals NHS Foundation Trust, York, United Kingdom

  ⨯
• Vicky Jespers,

  Affiliation Institute of Tropical Medicine, Antwerp, Belgium

  ⨯
• Brigitta A. Vcelar,

  Affiliation Polymun Scientific Immunbiologische Forschung GmbH, Vienna, Austria

  ⨯
• Charles J. Lacey

  * E-mail: charles.lacey@hyms.ac.uk

  Affiliation Centre for Immunology and Infection, Hull York Medical School, University of York, York, United Kingdom

  ⨯